MarginsXMarginsX
Home › Markets › Health Care › GDTC

CytoMed Therapeutics Limited (GDTC)

GDTC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.7739
-6.68% on the day
Market cap
$9.2M
Nano cap
Revenue · 2025
$252K
+395.9% on 2024
Net income · 2025
-$3.1M
-1227.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1873093/000149315226013813/0001493152-26-013813-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerGDTC on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountrySingapore
IPO year2023
SEC CIK0001873093
SEC industry codePharmaceutical Preparations
Incorporated inSingapore

Financials · 2025

LineValue
Revenue$252K
Net income-$3.1M
Operating incomeNot in SEC XBRL data
Net margin-1227.1%
Operating marginOperating income not reported
Revenue growth+395.9%
Cash$1.6M
Total assets$6.2M
P/E (computed)Net income was not positive
P/S (computed)36.3×

Warning signs

Cash runway
6.8 months
$1.6M cash at December 31, 2025
Share count, 1 year
+2.5%
2024-12-31 to 2025-12-31 · +2.6% over 3 years
Going-concern doubt
No
20-F filed March 31, 2026
Insider net buying, 12 months
$429K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"At present time, we manufacture limited quantities of cells for researchers and institutions on a non-profit, cost recovery basis for the purpose of research. 1 We have incurred losses since our incorporation and we expect to incur significant losses for the foreseeable future, which raise substantial doubt on our ability to continue as a going concern."
20-F 2026-03-31
Cash and burn$1.6M cash; operating cash flow -$719K a quarter.Report 2025-12-31
Shares outstanding11,828,435 (2025-12-31); 11,540,000 a year earlier; 11,529,328 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorWWC, P.C., San Mateo, California, United StatesPCAOB Form AP 2026-04-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $429K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$252K-$3.1M-$2.9M$1.6M$318K$252K20-F 2026-03-31
FY 2024
2024-12-31
$51K-$1.8M-$2.0M$3.7M$316K$51K20-F 2025-04-28
FY 2023
2023-12-31
Not filed-$3.1M-$2.6M$4.6M$335KNeeds four quarters20-F 2024-04-22
FY 2022
2022-12-31
Not filed-$2.3M-$1.0M$1.2M$600KNeeds four quarters20-F 2023-05-01

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-08-18
Latest annual report20-F2026-03-31
Latest quarterly / interim6-K2026-10-13

Source: SEC EDGAR submissions feed, 132 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.5%
1 month-4.7%
3 months-1.9%
Year to date-37.9%
1 year-56.8%
From 52-week high-58.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BFRGBullfrog AI Holdings Inc.$0.4878-9.92%$9.0M
LEXXLexaria Bioscience Corp.$4.41-0.68%$9.3M
PHIOPhio Pharmaceuticals Corp.$0.7522-2.44%$9.0M
VTGNVistagen Therapeutics Inc.$0.1843+2.11%$8.5M
AEONAEON Biopharma Inc.$0.1407-8.04%$10.1M
CLRBCellectar Biosciences Inc.$1.01-11.40%$10.1M
CALCCalciMedica Inc.$1.19-1.65%$8.2M
BFRIBiofrontera Inc.$0.5700-18.58%$10.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier